Finoriq research workspace
Zenas BioPharma, Inc. (ZBIO) SEC Filings & Filing Highlights
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development. Review ZBIO SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
- Company
- Zenas BioPharma, Inc. (ZBIO)
- Ticker
- ZBIO
- Market Cap
- $1.9B
- Latest Price
- $30.76
- Industry
- Biotech & Pharma
Zenas BioPharma, Inc. (ZBIO) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Zenas BioPharma, Inc. (ZBIO).
| Event | Form | Date |
|---|---|---|
| At the Annual Meeting, the stockholders of the Company voted on the following proposalsAt the Annual Meeting, the stockholders of the Company voted on the following proposals | 8-K5.07 | 2026-05-13 |
| On May 11, 2026, Zenas BioPharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockhol...On May 11, 2026, Zenas BioPharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As previously d... | 8-K5.02 | 2026-05-13 |
| Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 8-K2.02 | 2026-05-13 |
| Convertible Notes OfferingOn March 26, 2026, the Company entered into an underwriting agreement (the “Convertible Notes Underwriting Agreement”) with Jefferies LLC,... | 8-K8.01 | 2026-03-31 |
| Zenas BioPharma, Inc.: Material agreementOn March 31, 2026, Zenas BioPharma, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $200,000,000 a... | 8-K1.01 | 2026-03-31 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.